Psychedelic therapies show promise for psychological suffering at the end of life, but focusing too much on them may exaggerate the current evidence and pull resources from proven programs. The more urgent policy priority is to fix inequities in access to early, high-quality palliative and psychosocial care. Any discussion of expanding psychedelic access must also center equity concerns.
A disability-rights perspective is brought to the debate about whether psychedelic-assisted psychotherapy (PAP) researchers and clinicians should have personal experience with psychedelics. The authors argue that mandating or implying such experience can perpetuate ableism, because many psychiatric conditions and medications, including common antidepressants, may prevent safe psychedelic use. The field must prioritize disability inclusion among researchers and clinicians as PAP research and practice expand.